Literature DB >> 20028817

Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.

Neil Benson1, Joost de Jongh, Jonathan D Duckworth, Hannah M Jones, Henry E Pertinez, Jaiessh K Rawal, Tamara J van Steeg, Piet H Van der Graaf.   

Abstract

Recombinant alpha interferon (IFN-alpha) is used in the treatment of hepatitis C virus (HCV)-infected patients but is not optimal in terms of efficacy or tolerability. Toll-like 7 receptor (TLR-7) agonists stimulate the innate immune system to produce, among other cytokines, IFN-alpha and are being evaluated as alternative drugs to treat HCV infection. This paper describes the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling to understanding the behavior of a TLR-7 agonist [9-benzyl-8-hydroxy-2-(2-methoxyethoxy) adenine (BHMA)] in mice, using IFN-alpha as a biomarker. This is the first report of such a PK-PD model, and the conclusions may be of utility in the clinical development of TLR-7 agonists for HCV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028817      PMCID: PMC2825998          DOI: 10.1128/AAC.00551-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Hepatitis C--global prevalence (update).

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2000-01-21

Review 2.  The pharmacology of endosomal TLR agonists in viral disease.

Authors:  D R Averett; S P Fletcher; W Li; S E Webber; J R Appleman
Journal:  Biochem Soc Trans       Date:  2007-12       Impact factor: 5.407

Review 3.  Model-based drug development.

Authors:  R L Lalonde; K G Kowalski; M M Hutmacher; W Ewy; D J Nichols; P A Milligan; B W Corrigan; P A Lockwood; S A Marshall; L J Benincosa; T G Tensfeldt; K Parivar; M Amantea; P Glue; H Koide; R Miller
Journal:  Clin Pharmacol Ther       Date:  2007-05-23       Impact factor: 6.875

Review 4.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

Authors:  Meindert Danhof; Elizabeth C M de Lange; Oscar E Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

Review 5.  Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.

Authors:  Bart A Ploeger; Piet H van der Graaf; Meindert Danhof
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

Review 6.  Residence time of receptor-ligand complexes and its effect on biological function.

Authors:  Peter J Tummino; Robert A Copeland
Journal:  Biochemistry       Date:  2008-04-16       Impact factor: 3.162

7.  Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.

Authors:  David M Hammerbeck; Gary R Burleson; Craig J Schuller; John P Vasilakos; Mark Tomai; Elaine Egging; Felicia R Cochran; Susan Woulfe; Richard L Miller
Journal:  Antiviral Res       Date:  2006-08-18       Impact factor: 5.970

8.  Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent.

Authors:  Grant Langdon; John D Davis; Lynn M McFadyen; Mark Dewhurst; Neil S Brunton; Jaiessh K Rawal; Piet H Van der Graaf; Neil Benson
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

9.  Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine.

Authors:  Ashraf Yassen; Erik Olofsen; Jingmin Kan; Albert Dahan; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.

Authors:  Amy Thomas; Carl Laxton; Joanne Rodman; Nisha Myangar; Nigel Horscroft; Tanya Parkinson
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

View more
  7 in total

Review 1.  The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

Authors:  Abbi L Engel; Gregory E Holt; Hailing Lu
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

2.  89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model.

Authors:  Kirstin A Zettlitz; Felix B Salazar; Reiko E Yamada; K Ryan Trinh; Alex Vasuthasawat; John M Timmerman; Sherie L Morrison; Anna M Wu
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

Review 3.  Hepatitis C viral kinetics: the past, present, and future.

Authors:  Anushree Chatterjee; Patrick F Smith; Alan S Perelson
Journal:  Clin Liver Dis       Date:  2013-02       Impact factor: 6.126

4.  A Type I Interferon and IL-10 Induced by Orientia tsutsugamushi Infection Suppresses Antigen-Specific T Cells and Their Memory Responses.

Authors:  Chan-Ki Min; Hong-Ii Kim; Na-Young Ha; Yuri Kim; Eun-Kyung Kwon; Nguyen Thi Hai Yen; Je-In Youn; Yoon Kyung Jeon; Kyung-Soo Inn; Myung-Sik Choi; Nam-Hyuk Cho
Journal:  Front Immunol       Date:  2018-09-04       Impact factor: 7.561

5.  Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach.

Authors:  Priyata Kalra; Julian Brandl; Thomas Gaub; Christoph Niederalt; Jörg Lippert; Sven Sahle; Lars Küpfer; Ursula Kummer
Journal:  PLoS One       Date:  2019-02-13       Impact factor: 3.240

6.  Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model.

Authors:  Prashant Dogra; Javier Ruiz-Ramírez; Kavya Sinha; Joseph D Butner; Maria J Peláez; Manmeet Rawat; Venkata K Yellepeddi; Renata Pasqualini; Wadih Arap; H Dirk Sostman; Vittorio Cristini; Zhihui Wang
Journal:  medRxiv       Date:  2020-11-05

7.  Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model.

Authors:  Prashant Dogra; Javier Ruiz-Ramírez; Kavya Sinha; Joseph D Butner; Maria J Peláez; Manmeet Rawat; Venkata K Yellepeddi; Renata Pasqualini; Wadih Arap; H Dirk Sostman; Vittorio Cristini; Zhihui Wang
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.